The FDA accepts for review Nabriva Therapeutics' (NASDAQ:NBRV) resubmitted marketing application for Contepo (fosfomycin) for the treatment of complicated urinary tract infections. The agency's action date is June 19.
The company received a CRL last year citing deficiencies at one of its contract manufacturers.
Shares up 8% after hours.
Now read: Biogen: Buyback Signal »
Try Seeking Alpha PREMIUM for unlimited analysis on NBRV